Iterum reports Q2 2024 net loss $5.0M; PDUFA date Oct 25, 2024; AdCom Sept 9

Iterum Therapeutics plc

2024-Q2 EPS reported -$0.76

Net loss $5.0M Q2 2024 (vs $12.2M Q2 2023); cash $11.7M; expects runway into 2025 through PDUFA date.
FDA PDUFA action date October 25, 2024; Advisory Committee meeting September 9, 2024 on stewardship and patient population.
Closed rights offering August 9, 2024: $7.4M gross ($5.8M net) from 6.1M shares and warrants.
Received U.S. and Canadian patent allowances for sulopenem combinations expiring 2039-2041.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.